trending Market Intelligence /marketintelligence/en/news-insights/trending/aAjvgBFGNLWhqy_JaUKcNw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Arcadia Biosciences Q1 loss widens 64.8% YOY

Complying with International Financial Reporting Standard IFRS 9

Industries Most and Least Impacted by COVID-19 from a Probability of Default Perspective – September 2020 Update

Simplifying The Assessment of Company Fundamental Data

Infrastructure Issues: Understanding and Mitigating Risks

Arcadia Biosciences Q1 loss widens 64.8% YOY

Arcadia Biosciences Inc. said its first-quarter normalized net income was a loss of $33.57 per share, compared with the S&P Capital IQ consensus estimate of a loss of $2.20 per share.

The per-share loss grew 63.3% year over year from $20.56.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of $3.5 million, compared with a loss of $2.1 million in the year-earlier period.

Total revenue declined 40.8% year over year to $815,000 from $1.4 million, and total operating expenses grew 14.3% from the prior-year period to $4.5 million from $4.0 million.

Reported net income totaled a loss of $7.7 million, or a loss of $74.15 per share, compared to a loss of $3.5 million, or a loss of $33.80 per share, in the year-earlier period.